Limits...
Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors.

Bai X, Zhang Q, Wu S, Zhang X, Wang M, He F, Wei T, Yang J, Lou Y, Cai Z, Liang T - Sci Rep (2015)

Bottom Line: By analyzing the complementary determining region 3 (CDR3) gene sequence, we found no significant differences in the T cell receptor (TCR) repertoires between patients and healthy controls.In addition, clonotypes with low frequencies were found in significantly higher numbers in primary pancreatic tumors compared to blood samples from patients and healthy controls.The results imply that specific types of pancreatic cancer share potentially important immunological characteristics.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ABSTRACT
Pancreatic cancer has a poor prognosis and few effective treatments. The failure of treatment is partially due to the high heterogeneity of cancer cells within the tumor. T cells target and kill cancer cells by the specific recognition of cancer-associated antigens. In this study, T cells from primary tumor and blood of sixteen patients with pancreatic cancer were characterized by deep sequencing. T cells from blood of another eight healthy volunteers were also studied as controls. By analyzing the complementary determining region 3 (CDR3) gene sequence, we found no significant differences in the T cell receptor (TCR) repertoires between patients and healthy controls. Types and length of CDR3 were similar among groups. However, two clusters of patients were identified according to the degree of CDR3 overlap within tumor sample group. In addition, clonotypes with low frequencies were found in significantly higher numbers in primary pancreatic tumors compared to blood samples from patients and healthy controls. This study is the first to characterize the TCR repertoires of pancreatic cancers in both primary tumors and matched blood samples. The results imply that specific types of pancreatic cancer share potentially important immunological characteristics.

No MeSH data available.


Related in: MedlinePlus

Types and numbers of complementary determining region 3 (CDR3) in each group.Types and numbers of CDR3 were similar among groups; however, levels of diversity seemed higher in tissue and blood samples from patients compared to blood samples from healthy controls.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556988&req=5

f1: Types and numbers of complementary determining region 3 (CDR3) in each group.Types and numbers of CDR3 were similar among groups; however, levels of diversity seemed higher in tissue and blood samples from patients compared to blood samples from healthy controls.

Mentions: An Average of 18 (range, 13 to 36) million sequencing reads were acquired from each sample in our cohort. The numbers of clonotypes were 93,925 ± 32,490, 76,093 ± 34,020, and 93,527 ± 9,392 in the pancreatic cancer tissue (PCT), pancreatic cancer blood (PCB), and healthy volunteer blood (HVB) groups, respectively (Table S1). The numbers of unique peptides detected were 69,467 ± 27,035, 62,162 ± 30,135, and 70,265 ± 6,937 in the PCT, PCB, and HVB groups, respectively. The total numbers and types of CDR3 were at the same level in all groups, although samples from the patients showed a higher level of diversity within the two groups (Fig. 1).


Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors.

Bai X, Zhang Q, Wu S, Zhang X, Wang M, He F, Wei T, Yang J, Lou Y, Cai Z, Liang T - Sci Rep (2015)

Types and numbers of complementary determining region 3 (CDR3) in each group.Types and numbers of CDR3 were similar among groups; however, levels of diversity seemed higher in tissue and blood samples from patients compared to blood samples from healthy controls.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556988&req=5

f1: Types and numbers of complementary determining region 3 (CDR3) in each group.Types and numbers of CDR3 were similar among groups; however, levels of diversity seemed higher in tissue and blood samples from patients compared to blood samples from healthy controls.
Mentions: An Average of 18 (range, 13 to 36) million sequencing reads were acquired from each sample in our cohort. The numbers of clonotypes were 93,925 ± 32,490, 76,093 ± 34,020, and 93,527 ± 9,392 in the pancreatic cancer tissue (PCT), pancreatic cancer blood (PCB), and healthy volunteer blood (HVB) groups, respectively (Table S1). The numbers of unique peptides detected were 69,467 ± 27,035, 62,162 ± 30,135, and 70,265 ± 6,937 in the PCT, PCB, and HVB groups, respectively. The total numbers and types of CDR3 were at the same level in all groups, although samples from the patients showed a higher level of diversity within the two groups (Fig. 1).

Bottom Line: By analyzing the complementary determining region 3 (CDR3) gene sequence, we found no significant differences in the T cell receptor (TCR) repertoires between patients and healthy controls.In addition, clonotypes with low frequencies were found in significantly higher numbers in primary pancreatic tumors compared to blood samples from patients and healthy controls.The results imply that specific types of pancreatic cancer share potentially important immunological characteristics.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ABSTRACT
Pancreatic cancer has a poor prognosis and few effective treatments. The failure of treatment is partially due to the high heterogeneity of cancer cells within the tumor. T cells target and kill cancer cells by the specific recognition of cancer-associated antigens. In this study, T cells from primary tumor and blood of sixteen patients with pancreatic cancer were characterized by deep sequencing. T cells from blood of another eight healthy volunteers were also studied as controls. By analyzing the complementary determining region 3 (CDR3) gene sequence, we found no significant differences in the T cell receptor (TCR) repertoires between patients and healthy controls. Types and length of CDR3 were similar among groups. However, two clusters of patients were identified according to the degree of CDR3 overlap within tumor sample group. In addition, clonotypes with low frequencies were found in significantly higher numbers in primary pancreatic tumors compared to blood samples from patients and healthy controls. This study is the first to characterize the TCR repertoires of pancreatic cancers in both primary tumors and matched blood samples. The results imply that specific types of pancreatic cancer share potentially important immunological characteristics.

No MeSH data available.


Related in: MedlinePlus